Clinical Trial Update: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating regorafenib in selected GIST mutation subtypes after imatinib, in the second-line setting. The study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING